ArticleTranslational pediatrics2026
Concurrent chemoradiotherapy with temozolomide in newly pediatric diffuse intrinsic pontine glioma: clinical outcomes and safety analysis.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive pediatric brain tumors, with a median overall survival of less than 12 months despite radiotherapy remaining the current standard of care. This study aimed to evaluate the clinical outcomes and toxicity of concurrent radiotherapy with temozolomide followed by adjuvant therapy in newly diagnosed pediatric DIPG. Methods: Retrospective analysis of 24 consecutive pediatric DIPG patients (2006-2020) treated with focal radiotherapy (45-59.4 Gy) plus concurrent temozolomide (75 mg/m Results: Median age was 7 years (range, 3-16 years). H3K27M mutation was detected in 74% of biopsied cases (14/19). Post-radiotherapy imaging showed partial response in 12 patients (50%), stable disease in 9 (38%), and progression in 3 (12%). Median OS was 12.0 months [95% confidence interval (CI): 7.0-14.0]; median PFS was 9.0 months (95% CI: 7.0-12.0). One- and two-year OS rates were 54% and 8%, respectively. Grade 3-4 hematological toxicity occurred in 10 patients (42%): leucopenia (n=4), thrombocytopenia (n=6). No treatment-related deaths occurred. Conclusions: Concurrent chemoradiotherapy achieved encouraging response rates with manageable toxicity profile. However, survival outcomes remain limited, underscoring the need for novel therapeutic approaches targeting specific molecular pathways in this devastating malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.